novo nordisk glp-1 receptor agonist Evolution of GLP‐1 Agonists for Diabetes Treatment Novo Nordisk Receives FDA Approval

When a busy schedule prevents you from preparing a protein-rich meal, these convenient on-the-go options can help

Wang XY, Cleary EM, Thung SF, Venkatesh KK, Buschur EO

The primary endpoint is a three-point major adverse cardiovascular event endpoint that includes death from cardiovascular causes, non-fatal myocardial infarction (MI), or nonfatal stroke over a study period of 54 months

[8] [1] The Summary of Product Characteristics (SmPC) for all GLP-1 receptor agonists contains warnings about pancreatitis risk

SitagliptinScientific Conclusions and Grounds Recommending the Variation to the Terms of the Marketing Authorisation